Trial Profile
Clinical investigation of change of bone-related marker between denosumab and zoledronic acid in patients with treatment-naive,bone-metastasis prostate cancer:prospective, multiinstitutional,cohort study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid
- Indications Bone metastases; Prostate cancer
- Focus Biomarker; Pharmacodynamics
- 08 Dec 2015 New trial record